Literature DB >> 3342729

Propranolol and HBsAg-positive cirrhosis.

L Pagliaro, L Pasta, G D'Amico, M Traina, F Tinè.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342729     DOI: 10.1007/bf01535766

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  4 in total

1.  Hemodynamic effect of propranolol on portal hypertension in patients with HBsAg-positive cirrhosis.

Authors:  C W Kong; C S Lay; Y T Tsai; S D Lee; K H Lai; K J Lo; B N Chiang
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199

2.  A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report.

Authors:  D Lebrec; T Poynard; J Bernuau; E Bercoff; O Nouel; J P Capron; R Poupon; M Bouvry; B Rueff; J P Benhamou
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

3.  Survival and prognostic indicators in compensated and decompensated cirrhosis.

Authors:  G D'Amico; A Morabito; L Pagliaro; E Marubini
Journal:  Dig Dis Sci       Date:  1986-05       Impact factor: 3.199

4.  Propranolol--a medical treatment for portal hypertension?

Authors:  D Lebrec; O Nouel; M Corbic; J P Benhamou
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.